Please use this identifier to cite or link to this item:
http://10.1.7.192:80/jspui/handle/123456789/5321
Title: | Cardioprotective effects of magnesium valproate in type 2 diabetes mellitu |
Authors: | Raghunathan, Suchi |
Keywords: | IPFP0129 hyperglycaemia |
Issue Date: | 2014 |
Publisher: | Elsevier |
Series/Report no.: | IPFP0129; |
Abstract: | Wehaveevaluatedtheeffectofmagnesiumvalproate(210mg/kg/day,p.o.)intype2diabetesinduced cardiovascularcomplicationsinducedbystreptozotocin(STZ,90mg/kg,i.p.)inneonatalwistarrats.Various biochemical,cardiovascularandhemodynamicparametersweremeasuredattheendof8weeksof treatment.STZproducedsignificanthyperglycaemia,hypoinsulinemiaanddyslipidemia,whichwas preventedbymagnesiumvalproatetreatment.STZproducedincreaseinCreatinineKinase,C-reactive proteinandlactatedehydrogenaselevelsandtreatmentwithmagnesiumvalproateproducedreductionin these levels.STZproducedincreaseincardiacandLVhypertrophyindex,LV/RVratio,LVcollagendeposition andLVcardiomyocytediameterwhichweredecreasedbymagnesiumvalproatetreatment.Magnesium valproatealsopreventedSTZinducedhemodynamicalterationsandoxidativestress.Theseresultswere further supportedbyhistopathologicalstudiesinwhichmagnesiumvalproateshowedmarkedreductionin fibrosisandcardiac fiber disarray.Inconclusion,ourdatasuggeststhatmagnesiumvalproateisbeneficial as ananti-diabeticagentintype-2diabetesmellitusandalsopreventsitscardiaccomplications. |
Description: | European Journal of Pharmacology 728 (2014) 128–134 |
URI: | http://hdl.handle.net/123456789/5321 |
Appears in Collections: | Faculty Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
IPFP0129.pdf | IPFP0129 | 4.45 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.